JP2008199973A - Functional food product - Google Patents

Abstract

<P>PROBLEM TO BE SOLVED: To provide a functional food product having functions of lowering serum lipid, blood pressure and blood sugar while reducing accumulated fat tissues. <P>SOLUTION: Ion exchange water of 50 l is added to the entire herb of Glechoma hederacea of 5 kg, and it is heated at 90°C and extracted for 1 hr. After the extraction, solid/liquid separation by pressing is carried out to obtain an extract. The extract is vacuum-concentrated, thereafter freeze-drying is carried out to obtain a dried material. The died material is powdered by a crusher (Wonder Blender WB-1, Osaka Chemical) to obtain an extract of Glechoma hederacea of 1 kg through a 100 meshe sieve, additionally. <P>COPYRIGHT: (C)2008,JPO&INPIT

Description

  The present invention relates to a functional food effective in suppressing or preventing obesity, improving obesity constitution, reducing adipose tissue, and effective in improving symptoms of hypertension, hyperlipidemia, diabetics or their reserve army, that is, metabolic syndrome. .

  Major diseases called lifestyle-related diseases include obesity, hypertension, diabetes, and hyperlipidemia. These diseases are thought to be caused by obesity, particularly obesity with fat accumulated in the internal organs, rather than onset by individual causes. The state where various diseases are caused by visceral fat accumulation is called metabolic syndrome. According to a survey by the Ministry of Health, Labor and Welfare, 12.5% of men and 4.0% of women are listed as metabolic syndrome.

  Metabolic syndrome can cause arteriosclerosis, stroke, and cerebral infarction when risk factors (death quartet) are added to visceral obesity, and it is important to improve the symptoms of metabolic syndrome to prevent these diseases Is done.

  Conventionally, for those effective in metabolic syndrome, drinking oolong tea and Tochu tea has been preferred for the suppression, prevention and improvement of obesity. In addition, for the purpose of suppressing calorie intake, low energy foods, appetite-suppressing foods that make you feel full, digestion-absorption-suppressing foods that are difficult to digest even after eating have been used. In addition, there are foods that aim to suppress the increase in blood glucose level after meals or to lower blood pressure, but taking these foods does not necessarily prevent or improve obesity, and is also effective for metabolic syndrome. It is not the fundamental solution that is done.

As a conventional technique for inhibiting lipolysis for suppressing obesity, for example, it has been reported that compounds such as caffeine and theophylline promote lipolysis by biological hormones such as noradrenaline and adrenaline (see Patent Document 1). However, it is not preferable from the viewpoint of safety that it acts on the regulation of hormones as a food. In addition, fermented processed products (see Patent Document 2) that contain a large amount of minerals and have antioxidative activity and obesity-inhibiting action, and absorption of dietary fat by organic solvent extraction of plants, suppress fat metabolism of living tissues An obesity inhibitor by promoting (see Patent Document 3) has also been reported. However, high-concentration mineral intake or organic solvent extraction is not preferable for long-term intake.
JP-A-53-59038 JP 2004-141163 A JP 2004-91464 A

  The present inventors searched for a natural product that suppresses obesity, simultaneously suppresses blood pressure increase, suppresses blood sugar level increase, improves blood lipid level, and has high safety. The present invention has been found to exhibit an effect of reducing adipose tissue and exhibiting an effect in suppressing, preventing and improving obesity. Furthermore, it has been found that it has a blood pressure lowering effect, a postprandial blood sugar level increase inhibiting effect, and a blood cholesterol / neutral fat lowering effect, and has been confirmed to be effective for metabolic syndrome.

  The present invention provides functional foods that have high dietary safety and are effective in reducing accumulated adipose tissue and effective in lowering blood pressure, increasing blood sugar levels after meals, and improving blood lipid levels. The purpose is to do.

  In order to achieve the above-mentioned object, the functional food of the present invention has the function of reducing adipose tissue, lowering serum lipids, lowering blood pressure, and lowering blood glucose level, using the whole plant of Kakidooshi or its extract as an active ingredient. It is characterized by.

  In addition, the present invention provides functional foods that apply whole plant of persimmon or its extract to tablets, capsules, powders, etc., and foods that have the functionality to be added to its raw materials and general foods.

  In the plant used for the functional food of the present invention, the term “Kakidooshi” means Glechoma hederacea of the family Lamiaceae. Kakidooshi is also known as “Rensenso” or “Kantori-sou”, and has a kidney-shaped leaf. It blooms pale purple-blue flowers from April to May.

  Oyster persimmon can be used as it is, or dried and pulverized whole grass, leaves, stems, roots or flowers, but the functional food targeted by the present invention uses whole persimmon oak or its extract. It is preferable to do this.

  In addition, the extract of oysters means an extract obtained by extracting each part of oysters at room temperature or under heating, a concentrated solution thereof, and a dried product.

  As the organic solvent used to obtain the oyster extract of the present invention, any of a polar solvent and a nonpolar solvent can be used. For example, water, methanol, ethanol, propanol, butanol, propylene glycol, acetone , Ethyl acetate, ethers, benzene, toluene, hexane and the like. Of these, it is most preferable to use water as a solvent that can sufficiently exhibit the functionality of the present invention.

  The extraction condition is that extraction is performed at 1 to 15 hours, particularly 1 to 5 hours at a temperature of 15 to 105 ° C., preferably 70 to 95 ° C., using 2 to 200 parts by weight of solvent with respect to 1 part by weight of oyster pear. Is preferred.

  As the oyster extract, the extract can be used as it is, but the extract can be diluted, concentrated, or dried after removing the solvent, and can be prepared and used as powder or paste as necessary. Further, impurities can be removed using ion exchange, porous resin, or the like. In addition, treatments such as deodorization and decolorization can be performed by a known method.

  As shown in the examples described later, the kakidoshi of the present invention is a fat in a blood glucose increase suppression test, blood pressure decrease test, obesity suppression test and postprandial blood glucose increase suppression test in humans, lipid metabolism improvement test in humans. It showed tissue reduction, blood pressure reduction, blood glucose level increase suppression, and blood lipid level improvement. This physiological function is actually given to animals to verify its effect, and can be a functional food that is effective in improving the symptoms of metabolic syndrome.

  From the effect of the human test relating to Example 1 described later, the content of the active ingredient of the product of the present invention is 0.1 to 2 g, particularly 0.25 to 1.25 g, per day for an adult in a solvent-extracted dried product. It is preferable to mix and ingest.

Hereinafter, an Example is given and the functional food of this invention is demonstrated in detail. In addition, this invention is not limited to the following Example.
<Example 1 Production of Kakidoshi Extract>
50 liters of ion-exchanged water was added to 5 kg of oysters, and the mixture was heated to 90 ° C. and extracted for 1 hour. After extraction, solid-liquid separation was performed by pressing, and the extract was concentrated under reduced pressure and then freeze-dried to obtain a dried product. The dried product was pulverized with a pulverizer (Wonder Blender WB-1, manufactured by Osaka Chemical Co., Ltd.), and further 1 kg of oyster extract was obtained through a 100 mesh sieve. The general analysis results are shown in Table 1.

＜実施例２ カキドオシ抽出物入りパンの製造＞
次の組成割合でカキドオシ抽出物入りのパンを製造した。小麦粉１００g、イースト２．７g、イーストフード０．１g、乳化剤０．２g、ぶどう糖３g、砂糖１０g、乳製品３g、食塩１．５g、全卵１０g、酢酸ナトリウム０．３g、ハチミツ２g、マーガリン１５g、カキドオシ抽出物２g、水４８gを混ぜ、パン１個が約３４〜３６gになるように焼き上げた。このパン２個で１日あたりに摂取する量に定めた。なお、後述の実施例に示すヒト試験で使用するプラセボパンには、カキドオシ抽出物の代わりに、ローズマリーパウダーLBCP（ヤスマ製）０．２６％とココアブラウンSPY（ヤヱガキ醗酵技研製）０．２３％添加したものを用いた。

<Example 2 Production of bread with oyster extract>
Bread containing a kakidoshi extract was produced at the following composition ratio. 100 g flour, 2.7 g yeast, 0.1 g yeast food, 0.2 g emulsifier, 3 g glucose, 10 g sugar, 3 g dairy, 1.5 g salt, 10 g whole egg, 0.3 g sodium acetate, 2 g honey, 15 g margarine, 2 g of kakidoshi extract and 48 g of water were mixed and baked so that one bread was about 34 to 36 g. The amount consumed per day by these two breads was determined. In addition, in placebo bread used in the human test shown in the below-mentioned examples, instead of the kakidoshi extract, rosemary powder LBCP (manufactured by Yasuma) 0.26% and cocoa brown SPY (manufactured by Yagaki Fermentation Technology Co., Ltd.) 0.23% What was added was used.

  Next, the functional food of the present invention according to the above examples was subjected to a blood glucose level increase suppression test, a blood pressure decrease test, an obesity suppression test and a postprandial blood glucose level increase suppression test in humans, and a lipid metabolism improvement test. Results are shown.

<1: Rat blood glucose elevation suppression test>
The experimental animal used was a 5-week-old male Wistar rat obtained from CLEA Japan. The rats were divided into two groups (five animals in each group) of the control group and the product of the present invention (Example 1) so that the average body weights of rats were as much as possible. Blood was collected from the tail vein of a rat fasted for 20 hours, and the blood glucose level was measured with a Medisafe Reader (Terumo Corporation). Thereafter, distilled water was orally administered to the control group and the aqueous solution of Example 1 (100 mg / ml) was orally administered (5 ml / kg body weight) to the product group of the present invention. After 30 minutes, a 20% sucrose solution was orally administered (10 ml / kg body weight), and blood was collected after 30 minutes, 60 minutes, and 90 minutes, and blood glucose level was measured.
Moreover, the result of the blood glucose level rise suppression test in a rat is shown in FIG.

<2: Blood glucose level increase suppression test in humans>
Healthy adults (9 males and 7 females) were subjects, fasted after dinner the previous day, and after measuring fasting blood glucose level on the morning of the test day, the product of the present invention (Example 1) or a placebo capsule, about 0. 75 g was ingested. Five minutes later, retort curry (total energy 400 kcal, carbohydrate 77 g) was ingested, and blood glucose levels were measured 30, 60, 90 and 120 minutes after meals. Further, after a period of 5 days or longer, the same test was performed by taking a capsule different from the previous one. The human test was conducted by a person who explained the fact to the subject (informed consent) in accordance with the purpose of the Declaration of Helsinki and obtained consent.
Moreover, the result of the blood glucose level rise suppression test in a human is shown in FIG.

<3: Blood pressure increase suppression test in rats>
The experimental animals used were male SHR obtained from Hoshino Test Animal Breeding Center (Yashio City, Saitama Prefecture). The rats were divided into two groups (five animals in each group) of the control group and the product of the present invention (Example 1) so that the average body weights of rats were as much as possible. Blood pressure was selected indiscriminately from each group from 9:00 am on the first day of breeding and every 7 days, and 23 ° C using an unheated non-invasive blood pressure monitor Model MK-2000 (Muromachi Kikai, Tokyo). At the above room temperature, the systolic and diastolic blood pressures of the tail artery pressure were measured by the indirect (cuff) method without anesthesia. On the 25th day of the test, urine was collected for 24 hours using a separate urine collection cage (Tecniplast, rat metabolic cage), and sodium (Na) and potassium (K) in the urine and blood were collected using an electrode-type electrolyte analyzer Easy (Fukuyama Medical School, Chiba). Na excretion rate and K excretion rate were calculated by the following equations.

FIG. 3 shows a blood pressure increase suppression test in rats.
FIG. 4 shows the results of Na excretion rate (A) and K excretion rate (B).

<4: Obesity suppression test in rats>
The experimental animal used was male SHR / NDmcr-cp (cp / cp) (obese hypertensive rat: metabolic syndrome model animal) obtained from Japan SLC (Hamamatsu City). For comparison, the same test was performed on WKY / Izm of healthy rats and non-obese sibling SHR / NDmcr-cp (+ / +). The rats were divided into two groups (five animals in each group) of the control group and the product of the present invention (Example 1) so that the average body weights of rats were as much as possible. Blood pressure was selected indiscriminately from each group from 9:00 am on the first day of breeding and every 7 days, and 23 ° C using an unheated non-invasive blood pressure monitor Model MK-2000 (Muromachi Kikai, Tokyo). At the above room temperature, the systolic and diastolic blood pressures of the tail artery pressure were measured by the indirect (cuff) method without anesthesia. Blood was collected from the tail immediately after blood pressure measurement, and blood glucose levels and serum lipids (total cholesterol (TC), high density lipoprotein cholesterol (HDL-C), triglyceride (TG), phospholipid (PL)) were measured. . HDL-C was subtracted from TC to obtain ultra-low density lipoprotein cholesterol (VLDL-C) + low density lipoprotein cholesterol (LDL-C). The arteriosclerosis index (AI) was calculated from the ratio of HDL-C and VLDL-C + LDL-C. 90 days after the test, ether was anesthetized, blood was collected from the abdominal aorta, and the liver was immediately removed. Liver weight and liver TC, TG, and PL were measured. Leptin and adiponectin in the blood were also quantified. Next, Table 2 shows the results of the obesity suppression test in rats.

図６には肝臓脂質レベルの結果を示している。
また、図７には血清レプチンとアディポネクチンの結果を示している。

FIG. 6 shows the results of liver lipid levels.
FIG. 7 shows the results of serum leptin and adiponectin.

<5: Lipid metabolism improvement test in humans>
Forty healthy women were used as subjects and divided into two groups (20 each) of placebo group and product of the present invention (Example 2) group so that the average weight was the same. Fasted after dinner the day before, blood was collected on the morning of the test, blood pressure was measured, and body composition sites were measured. From this day, 2 breads or placebo breads of Production Example 2 were taken every day for 2 months. The amount of the oyster extract contained in this bread is 0.77 g. Blood pressure measurement every two weeks, body composition site-specific measurement and blood sampling test every other month were performed. The human test was conducted by a person who explained the fact to the subject (informed consent) in accordance with the purpose of the Declaration of Helsinki and obtained consent. The results are shown in Table 5.

＊は、vs. 試験前 （paired t-test, p<０．０５）において有意差を示す
＊＊は、vs. 試験前 （paired t-test, p<０．０１）において有意差を示す
＃は、vs. プラセボ （paired t-test, p<０．０５）において有意差を示す

* Indicates a significant difference before vs. test (paired t-test, p <0.05) ** indicates a significant difference before vs. test (paired t-test, p <0.01) # Shows significant difference in vs. placebo (paired t-test, p <0.05)

It is a graph which shows the blood glucose level rise suppression test result in a rat. It is a graph which shows the blood glucose level rise suppression test result in a human. It is a graph which shows the blood pressure rise suppression test result in a rat. It is a graph which shows the result of Na excretion rate (A) and K excretion rate (B). It is a graph which shows transition of a blood pressure value. It is a graph which shows the result of a liver lipid level. It is a graph which shows the result of serum leptin and adiponectin.

Claims (4)

 A functional food characterized by having a whole body of oysters or an extract thereof as an active ingredient and having functions of reducing adipose tissue, lowering serum lipids, lowering blood pressure and lowering blood glucose levels.  2. The functional food according to claim 1, which is effective for metabolic syndrome.  The functional food according to claim 1 or 2, wherein the whole plant of persimmon oak or its extract is made into a tablet, capsule or powder.  3. The functional food according to claim 1 or 2, wherein the whole plant of persimmon oak or an extract thereof is added to a general food.

Images